Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filing of retatrutide, a key obesity treatment, in early 2027. Despite this momentum, risks include a potential price war with Novo Nordisk, which plans significant price cuts on its competing drug Wegovy in 2027, and a concentrated revenue base from a few products. Analysts remain bullish with a 16.6% upside price target of $1,478.22, but caution that pricing pressures could impact future growth.
As of Oct 19, 2026 23:41 WIB, Eli Lilly (LLY) trades at USD 1,246.84, close to its 52-week high of $1.28K, while Novo Nordisk (NVO) is at USD 38.47, significantly below its 52-week high of $63.98. Despite Eli Lilly's strong earnings and raised revenue guidance, its 1-day change is slightly negative at -0.81%, similar to Novo Nordisk's -0.93%. Eli Lilly's market cap of $1.12T dwarfs Novo Nordisk's $171.83B, highlighting the scale difference between the two companies amid ongoing competition.
Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achi...
Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipi...
Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptio...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
